MiMedx
1234 Airport Road
Suite 105
Destin
Florida
32541
United States
Tel: 850-269-0000
Website: http://www.mimedx.com/
463 articles about MiMedx
-
Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
8/26/2022
The Cato T. Laurencin Regenerative Engineering Founders’ Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering.
-
MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts
7/27/2022
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the formation of a Regenerative Medicine Scientific Advisory Board.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers.
-
MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
7/20/2022
MiMedx Group, Inc., a transformational placental biologics company, announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022.
-
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer
7/18/2022
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today.
-
MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting
6/7/2022
MiMedx Group, Inc. announced that, based on the preliminary vote count provided by its proxy solicitor, shareholders have approved all proposals set forth by the Company at the 2022 Annual Meeting of Shareholders, including the reelection of both of MIMEDX’s directors, Dr. Phyllis Gardner and James L. Bierman, and the proposals on say-on-pay and the Company’s qualified employee stock purchase plan.
-
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders
6/3/2022
MiMedx Group, Inc., a transformational placental biologics company, reminded shareholders to pre-register for the upcoming 2022 Annual Meeting of Shareholders, by no later than 9:00 a.m. Eastern Time on Monday, June 6, 2022.
-
Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.
-
MIMEDX Addresses Presentation by Prescience Point
6/2/2022
MiMedx Group, Inc., a transformational placental biologics company, addressed the highly misleading presentation published by Prescience Point on May 31, 2022, which mischaracterizes important facts and relies on outdated and irrelevant information.
-
MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns
5/31/2022
MiMedx Group, Inc., a transformational placental biologics company, announced receiving a $4.6 Million award to evaluate PURION® processed Dehydrated Human Amnion Chorion Membrane as an advanced treatment option for wound and burn care.
-
MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders
5/31/2022
MiMedx Group, Inc., a transformational placental biologics company, mailed a letter to shareholders from Board Chair Dr. M. Kathleen Behrens in connection with its 2022 Annual Meeting of Shareholders scheduled for Tuesday, June 7, 2022, at 9:00 a.m. Eastern Time, which will be held in virtual format.
-
MIMEDX to Participate at Upcoming Investor Conferences - May 05, 2022
5/5/2022
MiMedx Group, Inc., a transformational placental biologics company, announced that senior management will participate in the following investor conferences.
-
MIMEDX Announces First Quarter 2022 Operating and Financial Results
5/3/2022
MiMedx Group, Inc., a transformational placental biologics company, announced the filing of its first quarter 2022 Form 10-Q for the period ended March 31, 2022.
-
MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4
4/20/2022
MiMedx Group, Inc. today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after the market close on Tuesday, May 3, 2022.
-
MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring
4/5/2022
MiMedx Group, Inc., a transformational placental biologics company, announced it will sponsor a lunch symposium at the Symposium on Advanced Wound Care Spring on April 6-10 in Phoenix, Arizona.
-
WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers Nationwide
3/16/2022
Leading wound care management and clinical services provider, WoundGenex, announced a strategic partnership with MiMedx Group, Inc., a transformational placental biologics company, to launch an exclusive version of WoundGenex's Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.
-
MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
2/28/2022
MiMedx Group, Inc., a transformational placental biologics company, announced the filing of its 2021 Annual Report on Form 10-K for the year ended December 31, 2021.
-
MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28
2/14/2022
MiMedx Group, Inc., a transformational placental biologics company, announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close on Monday, February 28, 2022.
-
MIMEDX Outlines Key Strategic Milestones for 2022
1/10/2022
MiMedx Group, Inc., a transformational placental biologics company, provided a recap of key 2021 accomplishments and outlined strategic milestones planned for 2022.
-
MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
1/4/2022
MiMedx Group, Inc. announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.